Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Relative <i>APOBEC3A</i> and MeV <i>M</i> mRNA quantification upon MeV infections in cells stably expressing DNase I. by Pierre Khalfi (7868252)

Prenatal alcohol exposure (PAE) decreases brain and body weights at E14 and P0. by Danielle Sambo (6077924)

Evolution of the adjusted geometric mean plasma values of homocysteine from baseline through the 4.7 years of follow-up (with adjustment for sex, baseline plasma creatinine, type o... by Leopold K. Fezeu (5309333)

V2 vasopressin receptor abundance. by Sophie Constantin Lütken (689916)

Subjects:

Reformation of oxygen gradient in a disturbed sediment. by Xuegang Mao (599968)

Subjects:

Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction. by Haruka Mori (8082215)

“…<p>(A–F) the neural activity of the RID changes during the transition periods from backward to forward locomotion (A–C) and from forward to backward locomotion (D–F) in the mock (A: p = 1.5 × 10⁻⁵; D: p = 5.5 × 10⁻¹³), 5-HT exposed (B: p = 0.092; E: p = 0.79), and <i>mod-1</i> mutant (C: p = 0.081; F: p = 0.93) groups. …”

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Decreased <i>Pax2</i> expression in <i>p53^−/−</i> embryonic kidneys. by Zubaida Saifudeen (135684)

“…<b>B</b>) In situ hybridization. Decreased expression of <i>Pax2</i> mRNA at E12.5. …”

HemaMax administration decreased leukopenia (a) and thrombocytopenia (b) at nadir in irradiated, unsupported rhesus monkeys. by Lena A. Basile (331369)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Effect of SNX5 S226 phosphorylation on macropinocytosis. by Nao Itai (5954666)

Subjects:

Automated wound healing assay showing decreased motility of IL-4 treated HCAEC. by Tom Skaria (2733439)

Mean value of ENSS and subscales. by Phu Dinh Vu (19429477)

Subjects:

Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

“…</p> Human primary cells and human and mouse established cell lines were treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours. The cells were then harvested and incubated with propidium iodide, and DNA content was determined using a FACS Caliber (Becton-Dickinson). …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”